These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36528478)

  • 21. Substantial family history of prostate cancer in black men recruited for prostate cancer screening: results from the Prostate Cancer Risk Assessment Program.
    Mastalski K; Coups EJ; Ruth K; Raysor S; Giri VN
    Cancer; 2008 Nov; 113(9):2559-64. PubMed ID: 18816608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How can we recruit more men of African or African-Caribbean ancestry into our research? Co-creating a video to raise awareness of prostate cancer risk and the PROFILE study.
    Hainsworth E; McGrowder E; McHugh J; Bancroft E; Mahabir S; Webber W; Eeles R; Cruickshank S
    Res Involv Engagem; 2022 Apr; 8(1):14. PubMed ID: 35436967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The feasibility of epidemiological research on prostate cancer in African men in Ibadan, Nigeria.
    Agalliu I; Adebiyi AO; Lounsbury DW; Popoola O; Jinadu K; Amodu O; Paul S; Adedimeji A; Asuzu C; Asuzu M; Ogunbiyi OJ; Rohan T; Shittu OB
    BMC Public Health; 2015 Apr; 15():425. PubMed ID: 25927535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
    Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
    Lee DJ; Hausler R; Le AN; Kelly G; Powers J; Ding J; Feld E; Desai H; Morrison C; Doucette A; Gabriel P; Genetics Center R; Judy RL; Weaver J; Kember R; Damrauer SM; Rader DJ; Domchek SM; Narayan V; Schwartz LE; Maxwell KN
    Eur Urol; 2022 Jun; 81(6):559-567. PubMed ID: 34711450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: A population-based, propensity score analysis.
    Antwi S; Everson TM
    Cancer Epidemiol; 2014 Aug; 38(4):435-41. PubMed ID: 24802851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications.
    Brandão A; Paulo P; Teixeira MR
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of prostate cancer family history with histopathological and clinical characteristics of prostate tumors.
    Spangler E; Zeigler-Johnson CM; Malkowicz SB; Wein AJ; Rebbeck TR
    Int J Cancer; 2005 Jan; 113(3):471-4. PubMed ID: 15455347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
    Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
    Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.
    Shi Z; Platz EA; Wei J; Na R; Fantus RJ; Wang CH; Eggener SE; Hulick PJ; Duggan D; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Xu J
    Eur Urol; 2021 Mar; 79(3):419-426. PubMed ID: 33257031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer.
    Shoaibi A; Rao GA; Cai B; Rawl J; Haddock KS; Hébert JR
    Prostate; 2017 Feb; 77(2):173-184. PubMed ID: 27699819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy.
    Thalgott M; Kron M; Brath JM; Ankerst DP; Thompson IM; Gschwend JE; Herkommer K
    World J Urol; 2018 Feb; 36(2):177-185. PubMed ID: 29164326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PRState: Incorporating genetic ancestry in prostate cancer risk scores for men of African ancestry.
    Pagadala MS; Linscott JA; Talwar JV; Seibert TM; Rose B; Lynch J; Panizzon M; Hauger R; Hansen MH; Sammon JD; Hayn MH; Kader K; Carter H; Ryan ST
    BMC Cancer; 2022 Dec; 22(1):1289. PubMed ID: 36494783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer.
    Gregg JR; Kim J; Logothetis C; Hanash S; Zhang X; Manyam G; Muir K; ; Giles GG; Stanford JL; Berndt SI; Kogevinas M; Brenner H; Eeles RA; ; Wei P; Daniel CR
    Eur Urol Oncol; 2023 Jun; 6(3):282-288. PubMed ID: 35995710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    Johnston TJ; Shaw GL; Lamb AD; Parashar D; Greenberg D; Xiong T; Edwards AL; Gnanapragasam V; Holding P; Herbert P; Davis M; Mizielinsk E; Lane JA; Oxley J; Robinson M; Mason M; Staffurth J; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Prescott S; Paul A; Powell P; Rosario D; Rowe E; Donovan JL; Hamdy FC; Neal DE;
    Eur Urol; 2017 Mar; 71(3):381-388. PubMed ID: 27720537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
    Bryant AK; D'Amico AV; Nguyen PL; Einck JP; Kane CJ; McKay RR; Simpson DR; Mundt AJ; Murphy JD; Rose BS
    Cancer; 2018 Jul; 124(14):2939-2947. PubMed ID: 29727915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of prostate cancer associated with a family history in an era of rapid increase in prostate cancer diagnosis (Australia).
    Staples MP; Giles GG; English DR; McCredie MR; Severi G; Cui JS; Hopper JL
    Cancer Causes Control; 2003 Mar; 14(2):161-6. PubMed ID: 12749721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.
    Na R; Labbate C; Yu H; Shi Z; Fantus RJ; Wang CH; Andriole GL; Isaacs WB; Zheng SL; Helfand BT; Xu J
    JAMA Netw Open; 2019 Dec; 2(12):e1918145. PubMed ID: 31880795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.